PORTFOLIO NEWS NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology January 12, 2021 Read More » ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones January 11, 2021 Read More » eFFECTOR Appoints Mike Byrnes as Chief Financial Officer January 7, 2021 Read More » Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer January 7, 2021 Read More » Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies January 7, 2021 Read More » NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock PDF Version January 5, 2021 Read More » A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers December 23, 2020 Read More » ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 December 21, 2020 Read More » NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors December 9, 2020 Read More » Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing December 8, 2020 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology January 12, 2021 Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones January 11, 2021 Read More »
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer January 7, 2021 Read More »
Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies January 7, 2021 Read More »
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock PDF Version January 5, 2021 Read More »
A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers December 23, 2020 Read More »
ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 December 21, 2020 Read More »
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors December 9, 2020 Read More »
Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing December 8, 2020 Read More »
